



# **Il lavoro e le raccomandazioni della Joint Action iPAAC sugli screening: confronto con le raccomandazioni della Cancer Mission**

---

**Roberta De Angelis**

ISTITUTO SUPERIORE DI SANITA'

Dipartimento di Oncologia e Medicina Molecolare, Unità di Epidemiologia dei Tumori e Genetica

[roberta.deangelis@iss.it](mailto:roberta.deangelis@iss.it)



Co-funded by  
the Health Programme  
of the European Union



## Innovative Partnership for Action Against Cancer (iPAAC)

- azione congiunta della Commissione Europea e 24 Stati Membri (Third Health Programme 2014-2020)
- Obiettivo: promuovere l'implementazione di approcci innovativi nel controllo del cancro (*mutual learning*)
- Target : decisore politico
- Main outcome: Roadmap on implementation and sustainability of recommendations and strategies to advance cancer control
- Europe's Beating Cancer Plan, EU4 Health e Cancer Mission

- **WP 5 – Prevention and Screening** – *Cancer Society of Finland (CSF)*
- WP 6 – Genomics in Cancer Control and Care – *Belgian Cancer Centre*
- WP 7 – Cancer Information and Registration – *Italian National Institute of Health - ISS*
- WP 8 – Challenges in Cancer Care - *Catalan Institute of Oncology - ICO*
- WP 9 – Innovative Therapies in Cancer – *French National Institute of Cancer - INCa*
- WP 10 –Governance of Integrated and Comprehensive Cancer Care – *German Federal Ministry of Health and German Cancer Society (DKG)*

# IL CONSORZIO ITALIANO IN IPAAC

---

- ISS Competent Authority for Italy
- MoH (Associated Partner)
- ISS Third Parties
  1. CRO, Aviano, WP 7,9
  2. INT Milano, WP 7,8,10
  3. IOV, Padova, WP 5,6,10
  4. ISPRO, Firenze WP 5,7,10
  5. Regione Emilia Romagna, AUSL-RE, Reggio Emilia, WP 6,8
  6. UNIVERSITA' CATTOLICA SACRO CUORE, Roma WP 6
  7. UNIVERSITA' LA SAPIENZA, Roma WP 5,10
  8. UNIVERSITA' di FOGGIA , Foggia WP 7

1. Population-based screening programmes
2. Innovations of programmes and risk stratified screening
3. New potential screenings (lung, prostate)

<https://www.ipaac.eu/en/work-packages/wp5/>

# POPULATION-BASED PROGRAMMES

- Cervical, breast and colorectal cancer (EU Council recommendation, 2003)

## PRIORITY

**Reduce disparities** between (and within) MS, and **solve inadequate implementation**

## AREAS OF INTERVENTION

- Monitoring systems to measure and foster **quality** improvement
- **Legal framework** enabling systematic quality assurance and evaluation
- **Networks** of experts to share experiences and develop effective solutions in critical settings

Recommendation Cancer Mission	Topic
4	<b>Optimize existing screening programmes</b>  Quality assessment tools, exchange of good practice, twinning
9	<b>Health equity across the continuum of the disease</b>  Inequity in access and quality of cancer prevention and screening

# INNOVATION & RISK-STRATIFIED SCREENING

- Risk-stratified approaches (HPV test, genetic mutations, family history, ...)

## CHALLENGES

**Balance of benefits and harms** through quality assessment tools

- lifetime monitoring risks/benefits of various options (survival and quality of life)
- real time assessment with validated early indicators of effectiveness (advanced stage)

## Optimise use of resources

- Logistics and organizational requirements to assess feasibility of implementation

Recommendation Cancer Mission	Topic
4	<b>Develop novel approaches for screening</b>
	Individualised approaches to screening
	Cost-effectiveness modelling

# INNOVATION & RISK-STRATIFIED SCREENING

- Risk-stratified approaches (HPV test, genetic mutations, family history, ...)

## CHALLENGES

### Balance of benefits and harms

- Lifetime benefits and harms of various options (survival and quality of life)
- Adopt validated early indicators of effectiveness (advanced stage)

### Optimise use of resources

- Logistics and organizational requirements

### Training health professionals

- Oncogenomics: impact on individualised screening, core curriculum and pilot e-learning WP 6

Recommendation Cancer Mission	Topic
4	<b>Develop novel approaches for screening</b>
	Individualised approaches to screening
	Cost-effectiveness modelling
9	<b>Health equity across the continuum of the disease</b>
	Improving health literacy, professional expertise (training for healthcare professionals)



# NEW POTENTIAL SCREENINGS

## Lung cancer, low-dose CT

- Further **implementation research** needed: target population, ways to reach it, integration with smoking cessation intervention
- Lifetime assessment of benefits/harms
- HTA and challenges in organization of care services

## Prostatic cancer

- Controversial results of trials using PSA-test
- Contradictory messages and recommendations
- No clear evidence for novel technologies reducing biopsies and invasive treatment for low-risk cancers

### Recommendation 4 Cancer Mission

**Develop novel approaches for screening and early detection**

Innovative screening methods

Cost-effectiveness modelling

Effective communication strategies to enhance citizens' understanding

# WP 5 RECOMMENDATIONS ON SCREENING: FINAL REPORT

## New openings of cancer screening in Europe

Work Package 5, task 5.2. Cancer Screening:  
Conference report

**Authors:** Ahti Anttila, Deependra Singh, Satu Lipponen, Stefan Lönnberg, Clarissa Bingham, Kaarina Tamminiemi, Ana Molina-Barceló, Marta Hernández-García, Paolo Giorgi Rossi, Marco Zappa - A.A., Sa.L., St.L., D.S., C.B. and K.T. from the Cancer Society of Finland, Helsinki; A.M.B., M.H.-G. from the Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO, Valencia; P.G.R. from the Epidemiology Service in Azienda USL-IRCCS di Reggio Emilia, Italy; M.Z. from the Istituto per lo studio, la prevenzione e la rete oncologica (ISPRO), Florence

## WP 5 Helsinki Conference 5/12/2019

WP5 task 5.2 Cancer Screening, direct link to the report

- <https://www.ipaac.eu/res/file/20191205-wp5-helsinki/20191205-helsinki-conference-report.pdf>

All materials including presentations

- <https://www.ipaac.eu/news-detail/en/29-new-openings-of-cancer-screening-in-europe/>